Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 3
1974 3
1975 9
1976 12
1977 43
1978 35
1979 28
1980 55
1981 44
1982 47
1983 58
1984 75
1985 74
1986 65
1987 66
1988 54
1989 63
1990 53
1991 71
1992 67
1993 53
1994 33
1995 42
1996 27
1997 36
1998 38
1999 38
2000 44
2001 38
2002 42
2003 39
2004 42
2005 43
2006 40
2007 43
2008 35
2009 35
2010 40
2011 30
2012 43
2013 41
2014 31
2015 39
2016 37
2017 42
2018 35
2019 42
2020 51
2021 53
2022 46
2023 26

Text availability

Article attribute

Article type

Publication date

Search Results

2,050 results

Results by year

Filters applied: . Clear all
Page 1
Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial.
Heatwole C, Luebbe E, Rosero S, Eichinger K, Martens W, Hilbert J, Dekdebrun J, Dilek N, Zizzi C, Johnson N, Puwanant A, Tawil R, Schifitto G, Beck CA, Richeson JF, Zareba W, Thornton C, McDermott MP, Moxley R 3rd. Heatwole C, et al. Neurology. 2021 Jan 12;96(2):e228-e240. doi: 10.1212/WNL.0000000000011002. Epub 2020 Oct 12. Neurology. 2021. PMID: 33046619 Free PMC article. Clinical Trial.
OBJECTIVE: To assess mexiletine's long-term safety and effect on 6-minute walk distance in a well-defined cohort of patients with myotonic dystrophy type 1 (DM1). ...Changes in PR, QRS, and QTc intervals were similar in mexiletine- and placebo-treated partici …
OBJECTIVE: To assess mexiletine's long-term safety and effect on 6-minute walk distance in a well-defined cohort of patients w …
About the different faces of mexiletine.
Postema PG. Postema PG. Heart Rhythm. 2020 Nov;17(11):1951-1952. doi: 10.1016/j.hrthm.2020.06.013. Epub 2020 Jun 13. Heart Rhythm. 2020. PMID: 32544436 No abstract available.
Mexiletine.
Campbell RW. Campbell RW. N Engl J Med. 1987 Jan 1;316(1):29-34. doi: 10.1056/NEJM198701013160106. N Engl J Med. 1987. PMID: 3537793 Review. No abstract available.
Mexiletine.
Danilo P Jr. Danilo P Jr. Am Heart J. 1979 Mar;97(3):399-403. doi: 10.1016/0002-8703(79)90442-3. Am Heart J. 1979. PMID: 420082 No abstract available.
Mexiletine metabolites: a review.
Catalano A, Carocci A, Sinicropi MS. Catalano A, et al. Curr Med Chem. 2015;22(11):1400-13. doi: 10.2174/0929867322666150227145412. Curr Med Chem. 2015. PMID: 25723511 Review.
Mexiletine belongs to class IB antiarrhythmic drugs and it is still considered a drug of choice for treating myotonias. ...Mexiletine is extensive metabolized in humans via phase I and phase II reactions. ...
Mexiletine belongs to class IB antiarrhythmic drugs and it is still considered a drug of choice for treating myotonias. ...Mexilet …
Pharmacology, electrophysiology, and pharmacokinetics of mexiletine.
Woosley RL, Wang T, Stone W, Siddoway L, Thompson K, Duff HJ, Cerskus I, Roden D. Woosley RL, et al. Am Heart J. 1984 May;107(5 Pt 2):1058-65. doi: 10.1016/0002-8703(84)90175-3. Am Heart J. 1984. PMID: 6326558 Review.
The marked rate dependence of Vmax depression may explain mexiletine's lack of effect on normal conduction and its efficacy against ventricular tachyarrhythmias. ...Elimination half-life is 9 to 11 hours after intravenous or oral administration. Microsomal enzyme in …
The marked rate dependence of Vmax depression may explain mexiletine's lack of effect on normal conduction and its efficacy ag …
Clinical pharmacokinetics of mexiletine.
Labbé L, Turgeon J. Labbé L, et al. Clin Pharmacokinet. 1999 Nov;37(5):361-84. doi: 10.2165/00003088-199937050-00002. Clin Pharmacokinet. 1999. PMID: 10589372 Review.
The major metabolites are hydroxymethyl-mexiletine, p-hydroxy-mexiletine, m-hydroxy-mexiletine and N-hydroxy-mexiletine. Formation of hydroxymethyl-mexiletine, p-hydroxy-mexiletine and m-hydroxy-mexiletine is genetically determined …
The major metabolites are hydroxymethyl-mexiletine, p-hydroxy-mexiletine, m-hydroxy-mexiletine and N-hydroxy-mexilet …
Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.
Jarvis B, Coukell AJ. Jarvis B, et al. Drugs. 1998 Oct;56(4):691-707. doi: 10.2165/00003495-199856040-00016. Drugs. 1998. PMID: 9806111 Review.
EMs, but not PMs, are susceptible to drug interactions between mexiletine and drugs that inhibit CYP2D6 (e.g. quinidine). Moreover, mexiletine inhibits CYP2D6-mediated metabolism of metoprolol and cytochrome P450 1A2-mediated metabolism of theophylline. Phenytoin an …
EMs, but not PMs, are susceptible to drug interactions between mexiletine and drugs that inhibit CYP2D6 (e.g. quinidine). Moreover, …
Hemodynamic effects of mexiletine.
Shanks RG. Shanks RG. Am Heart J. 1984 May;107(5 Pt 2):1065-71. doi: 10.1016/0002-8703(84)90176-5. Am Heart J. 1984. PMID: 6372422 Review.
A review of studies of mexiletine, a class I antiarrhythmic drug, supports its use in patients with ventricular arrhythmias or in sinus rhythm. ...Some studies are open and others are controlled to compare mexiletine to placebo or to lidocaine. Mexiletine in …
A review of studies of mexiletine, a class I antiarrhythmic drug, supports its use in patients with ventricular arrhythmias or in sin …
[Mexiletine].
Goldhammer E, Abinader E. Goldhammer E, et al. Harefuah. 1985 Jan 15;108(2):105-7. Harefuah. 1985. PMID: 3996968 Hebrew. No abstract available.
2,050 results